(Reuters) – Pfizer Inc. has agreed to pay $ 345 million to settle claims from consumers claiming to overpay for EpiPens due to anti-competitive and unfair practices by the drug manufacturer and Mylan, the company that markets the emergency allergy treatment.
The proposed class action lawsuit was disclosed in an application by federal court in Kansas City, Kansas. The deal, which requires a judge's approval, would not settle claims against Mylan, who is scheduled to stand trial in January.
Paul Geller, the plaintiffs' lawyer, said they were "pleased that Pfizer resolved its share of this class action over the pricing of EpiPens."
Pfizer, which did not admit any wrongdoing, did not immediately respond to a request for
EpiPen is a handheld device that treats life-threatening allergic reactions by automatically injecting a dose of epinephrine.
The dispute followed a public outcry in 201
The lawsuit accused Mylan and Pfizer, who made EpiPen for Mylan, of engaging in anti-competitive behavior that
The settlement came after U.S. District Judge Daniel Crabtree f Last month, many but not all of the allegations against Mylan were dismissed.
The remaining antitrust claims relate to a patent settlement which the plaintiffs say delayed the launch. of a generic epinephrine autoinjector. Mylan has said it is "convinced" that its "conduct was legal and competitive."
Mylan agreed in 2017 to pay 465 million dollars to settle the US Department of Justice claims that it overcharged the government for EpiPen.